Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
ideaya生物科學已在MTAP缺失性膀胱癌患者中，聯合吉利德的Trodelvy（sacituzumab govitecan-hziy）對IDE397進行了一期試驗，首名患者已接受給藥。
Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
ideaya生物科學已經在MTAP基因缺失膀胱癌患者中使用IDE397與Gilead的Trodelvy（Sacituzumab Govitecan-hziy）聯合進行了一期試驗中第一名患者的服藥。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。